BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17428314)

  • 21. A laminin-rich basement membrane matrix influences estrogen receptor beta expression and morphology of MDA-MB-231 breast cancer cells.
    Neubauer H; Ruoff A; Paessler N; Solomayer E; Wallwiener D; Fehm T
    Oncol Rep; 2009 Feb; 21(2):475-81. PubMed ID: 19148525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen.
    Levy N; Paruthiyil S; Zhao X; Vivar OI; Saunier EF; Griffin C; Tagliaferri M; Cohen I; Speed TP; Leitman DC
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):201-7. PubMed ID: 19744542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The changes of estrogen receptor-beta variants expression in breast carcinogenesis: Decrease of estrogen receptor-beta2 expression is the key event in breast cancer development.
    Park BW; Kim KS; Heo MK; Yang WI; Kim SI; Kim JH; Kim GE; Lee KS
    J Surg Oncol; 2006 May; 93(6):504-10. PubMed ID: 16615154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    Oh DS; Troester MA; Usary J; Hu Z; He X; Fan C; Wu J; Carey LA; Perou CM
    J Clin Oncol; 2006 Apr; 24(11):1656-64. PubMed ID: 16505416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
    Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients.
    Altundag O; Altundag K; Gunduz M
    Med Hypotheses; 2004; 63(4):684-7. PubMed ID: 15325017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
    Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
    J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.
    Secreto FJ; Monroe DG; Dutta S; Ingle JN; Spelsberg TC
    J Cell Biochem; 2007 Aug; 101(5):1125-47. PubMed ID: 17520659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor subtypes in ovarian cancer: a clinical correlation.
    Chan KK; Wei N; Liu SS; Xiao-Yun L; Cheung AN; Ngan HY
    Obstet Gynecol; 2008 Jan; 111(1):144-51. PubMed ID: 18165403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients.
    Savinov AY; Remacle AG; Golubkov VS; Krajewska M; Kennedy S; Duffy MJ; Rozanov DV; Krajewski S; Strongin AY
    Cancer Res; 2006 Mar; 66(5):2716-24. PubMed ID: 16510592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
    Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
    Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERbeta exerts multiple stimulative effects on human breast carcinoma cells.
    Hou YF; Yuan ST; Li HC; Wu J; Lu JS; Liu G; Lu LJ; Shen ZZ; Ding J; Shao ZM
    Oncogene; 2004 Jul; 23(34):5799-806. PubMed ID: 15208676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
    Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
    Frasor J; Chang EC; Komm B; Lin CY; Vega VB; Liu ET; Miller LD; Smeds J; Bergh J; Katzenellenbogen BS
    Cancer Res; 2006 Jul; 66(14):7334-40. PubMed ID: 16849584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1.
    Lattrich C; Juhasz-Boess I; Ortmann O; Treeck O
    Oncol Rep; 2008 Mar; 19(3):811-7. PubMed ID: 18288420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.
    Chen M; Ni J; Chang HC; Lin CY; Muyan M; Yeh S
    Carcinogenesis; 2009 May; 30(5):841-50. PubMed ID: 19126643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.
    Yu K; Ganesan K; Miller LD; Tan P
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3288-96. PubMed ID: 16740749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components.
    Martineti V; Picariello L; Tognarini I; Carbonell Sala S; Gozzini A; Azzari C; Mavilia C; Tanini A; Falchetti A; Fiorelli G; Tonelli F; Brandi ML
    Endocr Relat Cancer; 2005 Jun; 12(2):455-69. PubMed ID: 15947116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.